XORTX Announces Results of Special Meeting of Shareholders
27 oct. 2023 17h30 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 27, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Date for Rescheduled Special Meeting of Shareholders
25 oct. 2023 17h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Rescheduling of Special Meeting of Shareholders
25 oct. 2023 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution
12 oct. 2023 07h00 HE
|
XORTX Therapeutics Inc.
ISS, a leading proxy advisory firm, recommends XORTX Therapeutics Inc.’s shareholders vote FOR the share consolidation resolution, stating that approving the share consolidation will “enhance the...
XORTX Calls Special Meeting of Shareholders
04 oct. 2023 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023
28 sept. 2023 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Participation at Upcoming Investor Conferences
11 sept. 2023 07h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 11, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Joins the Kidney Foundation and Kidney March
07 sept. 2023 07h00 HE
|
XORTX Therapeutics Inc.
● In Support of Research for Treating the 4 Million Canadians Who Have Chronic Kidney Disease Today ● CALGARY, Alberta, Sept. 07, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the...
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
29 août 2023 07h00 HE
|
XORTX Therapeutics Inc.
● XORTX’s Proprietary Formulation of Oxypurinol – XORLO™ – to Treat Progressive Kidney Disease Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD) ● CALGARY, Alberta, Aug. 29, 2023 ...
XORTX Appoints Chief Financial Officer
04 août 2023 17h00 HE
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...